跳至主要内容
临床试验/NCT00265174
NCT00265174Unknown不适用

Serum DNA Analysis: Potential Application for Diagnosis and Prognosis in Brain Cancer.

Hadassah Medical Organization1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2006年1月最近更新:
适应症

试验速览

阶段
不适用
入组人数
60
试验地点
1

研究概览

简要总结

Numerous studies document the ability of tumors to shed DNA into the blood stream. Circulating DNA can thus be recovered for analyses, representing a surrogate tumor material to test for potential applications in disease diagnosis and prognosis.

Detection of genetic alternation is one of the most important tests for cancer patient since they offen correlated with the clinical course, prognosis and chemosensitivity of primary brain tumors. Currently in brain tumor patients these molecular aberrations can be analyzed only on tumor tissue that was obtained at surgery or biopsy.

Paucity of pathologic samples or poor fixation technique often make the tissue samples unassessable for molecular aberrations.

Therefore, the ability to extract tumor DNA from peripheral blood holds a great clinical significance. Still, the molecular aberration evaluated on serum DNA should be correlated and verified by comparison to standard evaluations performed on tumor samples. Our study aim is to evaluate the feasibility of using serum DNA for routine diagnosis of tumor molecular aberrations.

详细描述

Backround:

Genetic and epigenetic abrasions like loss of hetherozygosity and hypermethylation of gene promoters are common aberration in gliomas. Detection of these aberrations serves as diagnostic and prognostic tool. Examples: 1. oligodendrogliomas patients with combined 1p/19q LOH within the tumor respond better to chemotherapy and have better prognosis, whereas LOH on chromosome 10q is a marker for worse prognosis. 2. GBM patients with hypermethylation of the promoter of methyl-guanine-methyl-transferase (MGMT) in the tumor respond better to alkylating agent and have better prognosis.

As sample materials for diagnosis should be easily accessible by a minimally invasive procedure, there has been much interest in the potential use of nucleic acid markers in the blood of patients with cancer.

It was demonstrated that LOH as well as hypermethylation could be detected in the plasma/serum of patients with a variety of malignancies, suggesting that circulating tumor-associated DNA in the blood of patients can be a key determinant in predicting genetic and epigenetic abrasions in the tumor.

Objectives of the study:

研究设计

研究类型
Observational
观察模型
Defined Population
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • LOW AND HIGH GRADE GLIOMAS

排除标准

  • NON GLIAL TUMORS

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验

Serum DNA Analysis: Potential Application for... | 临床试验